Abstract: The invention provides three orally administered ciprofloxacin formulations: The first formulation comprises 60-75 wt % of ciprofloxacin or at least one of pharmacologically acceptable salt; 0.3-10 wt % of pregelatinized starch as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant. The second formulation comprises 60-75 wt % of ciprofloxacin or its pharmacologically acceptable salt; 1-5 wt % of polyvinyl pyrrolidone as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant. The third formulation comprises 60-75 wt % of ciprofloxacin or at least one of pharmacologically acceptable salt; 1-8 wt % of polyvinyl alcohol as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant.